ReviewCurrent treatment options in oncology2015
Targeted Therapy in Biliary Tract Cancers.
Review in Current treatment options in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2017Pooled it
- HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?Cancer metastasis reviews · 2017Pooled it
- Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Journal of hematology & oncology · 2017Trial
- Article
- Role of chemotherapeutic drugs in immunomodulation of cancer.Current research in immunology · 2023Review
- The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.Journal of experimental & clinical cancer research : CR · 2022Review
- Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.Current oncology (Toronto, Ont.) · 2022Review
- Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer.Annals of translational medicine · 2021Article
- WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021Article
- High expression of PSMC2 promotes gallbladder cancer through regulation of GNG4 and predicts poor prognosis.Oncogenesis · 2021Article
- Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.Cancers · 2020Review
- Review
- Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score.Journal of oncology · 2020Article
- Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis.Biomedical reports · 2018Article
- Clinicopathological features and survival of gallbladder squamous cell carcinoma: analysis of 121 cases.International journal of clinical and experimental pathology · 2018Article
- Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.American journal of cancer research · 2018Article
- Immunotherapeutic Approaches to Biliary Cancer.Current treatment options in oncology · 2017Review
- Intrahepatic cholangiocarcinoma: current perspectives.OncoTargets and therapy · 2017Review
- Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.Current treatment options in oncology · 2016Review
- Molecular profiling of biliary tract cancer: a target rich disease.Journal of gastrointestinal oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementA paradigm shift towards molecular-based, personalized cancer therapeutics has occurred in recent years and a number of targeted drugs have emerged. Various targeted therapies like erlotinib, trastuzumab, and cetuximab have been approved in lung, breast, and colon cancers, respectively. Numerous clinical trials involving targeted drugs in biliary tract cancers are currently in progress, though none have been approved for this disease. Biliary tract cancers are divided into separate entities both anatomically and in terms of pathogenesis but are grouped together in most trials given their rarity. Combination chemotherapy involving cisplatin and gemcitabine is the current standard of care in the metastatic setting. In this review, we will discuss the various molecular pathways implicated in biliary tract cancers and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.